|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 14.2 1.85 11.53%
Head of Investor Relations and VP
Mr. Jorgen Winroth was appointed Vice President, Head of Investor Relations at Swedish Orphan Biovitrum AB, effective as of November 16, 2012. He has served as Director, Investor Relations for AstraZeneca North America for the past sixteen years. He has also served as Consultant providing strategic Investor Relations services to a number of Scandinavian companies including Hafslund Nycomed AS, AB SKF, Huhtamaki Oy. He also served as Vice President, Investor Relations at Pharmacia.
VP Since 2012
46 86 97 20 00 http://www.sobi.com
The company has return on total asset (ROA)
of 8.0 %
which means that it generated profit of $8.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 5.6 %
meaning that it generated $5.6 on every $100 dollars invested by stockholders.
The company has accumulated 53.55 M in total debt with debt to equity ratio (D/E) of 0.09 which may suggest the company is not taking enough advantage from borrowing. Swedish Orphan Biovitrum AB has Current Ratio of 1.74 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.